Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMED Study: Buprenorphine/Naloxone Microdosing vs. Standard Dosing in EDs
NCT04893525Phase 3Recruiting
- Sponsor
- University of British Columbia
- Start
- Jul 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buprenorphine + naloxone in opioid use disorder (OUD), sponsored by University of British Columbia. Started Jul 2021; status: recruiting.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04893525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893525.